Chemical Nameixekizumab
Dosage FormInjection (subcutaneous; 80 mg/6 mL)
Drug ClassMonoclonal antibodies
SystemMusculoskeletal, Skin
CompanyEli Lilly and Company
Approval Year2016


  • To treat adults with moderate-to-severe plaque psoriasis.
  • To treat active ankylosing spondylitis.
  • To treat active psoriatic arthritis.
Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Taltz (ixekizumab) Prescribing Information2019Eli Lilly and Company, Indianapolis, IN